Longitudinal Assessment of Health-Related Quality of Life in Men With Localized Prostate Cancer
Completed
Conditions studied: Prostate Cancer
In brief
The purpose of this study is to assess quality-of-life of men with prostate cancer. "Quality-of-life" means how you feel about your life as a result of your disease and its treatment. The investigators hope that this questionnaire will help show how prostate cancer treatments affect quality-of-life. It will help doctors and future patients to make better treatment choices. Some men may wish to have a more demanding treatment with a higher risk of harmful effects. Others may prefer a treatment that will have the smallest effect on their quality-of-life. This questionnaire will help us measure these effects and decide which is the best treatment for a given patient.
Key facts
- Study ID
- NCT00582842
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 1800
- Starts
- 2002-05-14
- Expected to finish
- 2022-12-21
- Last updated by the study team
- 2022-12-27
Who can join
Age: any. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- diagnosis of localized, untreated prostate cancer (clinical stages T1-3, Nx, M0)
- ability to read the English language
You may not qualify if…
- other cancer diagnosis for the past three years, except for non-melanoma skin cancer
- prior chemotherapy within the last three years; radiation therapy to the pelvis or prior pelvic surgery within the past three years
- prior neoadjuvant therapy, such as hormones (Bicalutamide use for less than or equal to 1 month would not constitute exclusion from study entry)
- For the cross-sectional component of the study, all patients identified to be free of disease at least ten years post -treatment will be considered eligible. Patients must have no clinical evidence of local, regional or distant recurrences. Patients must have the ability to read and understand English. Patients who received hormonal therapy will be eligible for the cross-sectional component of the study, but the duration of the hormonal therapy must be six months or less. the investigators have identified a cohort of patients who fit these criteria from our databases.
Where it is running
- Memoral Sloan Kettering Cancer Center — Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Cancer Center @ Suffolk — Commack, New York, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Memorial Sloan Kettering at Mercy Medical Center — Rockville Centre, New York, United States
- Memoral Sloan Kettering Cancer Center@Phelps — Sleepy Hollow, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.